Could a chemo drug tame rare vascular tumors?
NCT ID NCT03331250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small pilot study tested the drug eribulin (Halaven) in 13 people with two rare cancers of blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had already tried at least one other treatment. The study is now complete and no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Eribulin (Halaven)
What this could lead to
If it works, this could point toward a treatment option for rare blood vessel cancers like angiosarcoma and EHE.
What could go wrong
This is a very small pilot study with only 13 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States